Literature DB >> 21446989

Immunohistochemical staining with Melan-A of uninvolved sun-damaged skin shows features characteristic of lentigo maligna.

Anneli R Bowen1, Betsy N Perry Thacker, David E Goldgar, Glen M Bowen.   

Abstract

BACKGROUND: The greater density and unusual patterning of melanocytes in chronically sun-exposed skin complicates interpretation of intraoperative Melan-A immunohistochemical stained margins during margin-controlled surgery for lentigo maligna (LM) and lentigo maligna melanoma (LMM).
OBJECTIVE: To identify the immunohistochemical similarities and differences in melanocyte distribution between LM and LMM and chronically sun-exposed skin.
METHODS: Retrospective review of Melan-A-stained original biopsy specimens of LM and LMM and uninvolved sun-damaged skin (negative controls), from 70 LM and LMM cases from the University of Utah in 2008.
RESULTS: Histologic features commonly associated with LM were common in negative controls from chronically sun-exposed skin. Melanocyte confluence (27/70, 39%), stacking (34/70, 49%), theque formation (9/70, 13%), adnexal extension (59/68, 87%), and suprabasilar scatter (23/70, 33%) were observed in the negative controls from sun-damaged skin. Such features were present nearly uniformly in the LM and LMM specimens. Epidermal melanocyte density in LM and LMM differed significantly from that in negative controls (82.7 ± 29.3 and 25.6 ± 9.3 per × 400 field, respectively; p<.001).
CONCLUSION: Epidermal melanocytic features often ascribed to LM, such as melanocyte confluence, stacking, theque formation, adnexal extension, and suprabasilar scatter, are frequently observed in chronically sun-exposed Caucasian skin and may lead to overestimation of surgical margins.
© 2011 by the American Society for Dermatologic Surgery, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21446989     DOI: 10.1111/j.1524-4725.2011.01946.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  5 in total

1.  Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.

Authors:  Jessica M Donigan; Mark A Hyde; David E Goldgar; Michael L Hadley; Marianne Bowling; Glen M Bowen
Journal:  JAMA Dermatol       Date:  2018-08-01       Impact factor: 10.282

Review 2.  Lentigo maligna and lentigo maligna melanoma: contemporary issues in diagnosis and management.

Authors:  Karen L Connolly; Kishwer S Nehal; Klaus J Busam
Journal:  Melanoma Manag       Date:  2015-05-18

3.  Comparison of Melanocyte Density Counts in Topical Imiquimod-Treated Skin Surrounding Lentigo Maligna vs Control Biopsy Specimens.

Authors:  Shadai Flores; Nathan J Luby; Glen M Bowen
Journal:  JAMA Dermatol       Date:  2018-04-01       Impact factor: 10.282

4.  Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins.

Authors:  Cynthia M Magro; Sung-Eun Yang; Jonathan H Zippin; Artur Zembowicz
Journal:  Arch Pathol Lab Med       Date:  2012-12       Impact factor: 5.534

Review 5.  Reviewing Challenges in the Diagnosis and Treatment of Lentigo Maligna and Lentigo-Maligna Melanoma.

Authors:  Margit L W Juhász; Ellen S Marmur
Journal:  Rare Cancers Ther       Date:  2015-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.